Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Total Liabilities (2022 - 2025)

Atara Biotherapeutics' Total Liabilities history spans 4 years, with the latest figure at $58.7 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 71.54% year-over-year to $58.7 million; the TTM value through Dec 2025 reached $58.7 million, down 71.54%, while the annual FY2025 figure was $58.7 million, 71.54% down from the prior year.
  • Total Liabilities reached $58.7 million in Q4 2025 per ATRA's latest filing, down from $66.8 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $264.7 million in Q4 2023 to a low of $58.7 million in Q4 2025.
  • Average Total Liabilities over 4 years is $188.1 million, with a median of $217.3 million recorded in 2024.
  • Peak YoY movement for Total Liabilities: skyrocketed 37.09% in 2023, then tumbled 71.54% in 2025.
  • A 4-year view of Total Liabilities shows it stood at $249.8 million in 2022, then grew by 5.99% to $264.7 million in 2023, then decreased by 22.04% to $206.4 million in 2024, then crashed by 71.54% to $58.7 million in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Total Liabilities are $58.7 million (Q4 2025), $66.8 million (Q3 2025), and $71.9 million (Q2 2025).